ArticlePLoS computational biology2013
Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling.
Article in PLoS computational biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 citations in OpenAlex.
- Artificial intelligence-empowered, clinically-integrated multiomics research in thrombosis: a call to action.Research and practice in thrombosis and haemostasis · 2026Article
- Integrative phosphoproteomic analysis reveals co-regulatory phosphorylation networks of rhotekin in cancer progression.Discover oncology · 2026Article
- Bioinformatics Approaches in Noncoding RNAs Research.Experientia supplementum (2012) · 2026Review
- Multi-omics unravel heterogeneity of glucose metabolism reprogramming in gastric cancer.Clinical and experimental medicine · 2025Article
- Investigative needle core biopsies support multimodal deep-data generation in glioblastoma.Nature communications · 2025Article
- Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights.Clinical Medicine Insights. Oncology · 2025Review
- Does combining numerous data types in multi-omics data improve or hinder performance in survival prediction? Insights from a large-scale benchmark study.BMC medical informatics and decision making · 2024Article
- De novo identification of maximally deregulated subnetworks based on multi-omics data with DeRegNet.BMC bioinformatics · 2022Article
- Integrative Multi-Omics Approaches in Cancer Research: From Biological Networks to Clinical Subtypes.Molecules and cells · 2021Review
- Identification of FMR1-regulated molecular networks in human neurodevelopment.Genome research · 2020Article
- Review
- Connecting signaling and metabolic pathways in EGF receptor-mediated oncogenesis of glioblastoma.PLoS computational biology · 2019Article
- Discovering Altered Regulation and Signaling Through Network-based Integration of Transcriptomic, Epigenomic, and Proteomic Tumor Data.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Differential Integration of Transcriptome and Proteome Identifies Pan-Cancer Prognostic Biomarkers.Frontiers in genetics · 2018Article
- An Integrative Framework Reveals Signaling-to-Transcription Events in Toll-like Receptor Signaling.Cell reports · 2017Article
- Review
- Integrated systems biology analysis of KSHV latent infection reveals viral induction and reliance on peroxisome mediated lipid metabolism.PLoS pathogens · 2017Article
- Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens.PloS one · 2017Article
- Revealing disease-associated pathways by network integration of untargeted metabolomics.Nature methods · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Cellular signal transduction generally involves cascades of post-translational protein modifications that rapidly catalyze changes in protein-DNA interactions and gene expression. High-throughput measurements are improving our ability to study each of these stages individually, but do not capture the connections between them. Here we present an approach for building a network of physical links among these data that can be used to prioritize targets for pharmacological intervention. Our method recovers the critical missing links between proteomic and transcriptional data by relating changes in chromatin accessibility to changes in expression and then uses these links to connect proteomic and transcriptome data. We applied our approach to integrate epigenomic, phosphoproteomic and transcriptome changes induced by the variant III mutation of the epidermal growth factor receptor (EGFRvIII) in a cell line model of glioblastoma multiforme (GBM). To test the relevance of the network, we used small molecules to target highly connected nodes implicated by the network model that were not detected by the experimental data in isolation and we found that a large fraction of these agents alter cell viability. Among these are two compounds, ICG-001, targeting CREB binding protein (CREBBP), and PKF118-310, targeting β-catenin (CTNNB1), which have not been tested previously for effectiveness against GBM. At the level of transcriptional regulation, we used chromatin immunoprecipitation sequencing (ChIP-Seq) to experimentally determine the genome-wide binding locations of p300, a transcriptional co-regulator highly connected in the network. Analysis of p300 target genes suggested its role in tumorigenesis. We propose that this general method, in which experimental measurements are used as constraints for building regulatory networks from the interactome while taking into account noise and missing data, should be applicable to a wide range of high-throughput datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.